Significantly decreased LMK-CT score vs placebo at Week 24, with greater improvement at Week 52 in Trial 2 (secondary endpoint)1,2
CT scan of patient from clinical trial. Individual results may vary.
Change in LMK-CT scores in Trial 2 (Secondary endpoint)1,2
DUPIXENT DEMonSTRATED Statistically significant REDUCTIonS IN OPACIFICATION across ALL Individual SINUSES1,2
- Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.
- LSM, least squares mean; SOC, standard of care.